Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
TT11
i
Other names:
CD30.CAR-T, ATLCAR.CD30 cell therapy, ATLCAR.CD30 cells, CAR.CD30 T cell therapy, TT11, CD30.CAR-T cell therapy, TT11 CD30 CAR Ts
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(2)
News
Trials
Company:
Baylor Scott & White Research Institute, Tessa Therap, UNC Lineberger Comprehensive Cancer Center
Drug class:
CD30-targeted CAR-T immunotherapy
Related drugs:
‹
CART-30 (1)
4SCAR30273 (0)
ATLCAR.CD30.CCR4 cells (0)
CAR-T CD19/CD20/CD22/CD30 (0)
TT11X (0)
anti-CD30 CAR T cells (0)
CART-30 (1)
4SCAR30273 (0)
ATLCAR.CD30.CCR4 cells (0)
CAR-T CD19/CD20/CD22/CD30 (0)
TT11X (0)
anti-CD30 CAR T cells (0)
›
Associations
(2)
News
Trials
VERI cancer hierarchy
Reset Filters
TNFRSF8 positive
Non-Hodgkin’s Lymphoma
TNFRSF8 positive
Non-Hodgkin’s Lymphoma
TT11
Sensitive: C2 – Inclusion Criteria
TT11
Sensitive
:
C2
TT11
Sensitive: C2 – Inclusion Criteria
TT11
Sensitive
:
C2
TNFRSF8 positive
Hodgkin Lymphoma
TNFRSF8 positive
Hodgkin Lymphoma
TT11
Sensitive: C3 – Early Trials
TT11
Sensitive
:
C3
TT11
Sensitive: C3 – Early Trials
TT11
Sensitive
:
C3
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login